相关实验视频
Updated: Jun 20, 2026
08:41
Modeling Chemotherapy Resistant Leukemia In Vitro
Published on: February 9, 2016
9.0K
建模高风险威尔姆斯瘤可以发现治疗脆弱性的发现
Gui Ma1, Ang Gao1, Jiani Chen2
1McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, WI 53706, USA; Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI 53706, USA.
Cell reports. Medicine
|October 5, 2024
概括
一种针对高风险威尔姆斯瘤 (WT) 的新模型,称为WiT49-PRCs,有效地模仿了布拉斯泰姆主导的WT和转移. 这个模型确定了基因素脱乙酶 (HDAC) 抑制剂作为治疗儿科癌复发的强效药物.
科学领域:
- 在瘤学瘤学.
- 发展生物学 发展生物学
- 癌症研究 癌症研究
背景情况:
- 威尔姆斯瘤 (WT) 是最常见的儿科癌,标准化疗往往对差异较小的瘤类型失败.
- 高风险WT的复发需要改善治疗开发的模型.
研究的目的:
- 开发一种临床前模型,用于高风险,布拉斯泰姆主导的威尔姆斯瘤 (WT).
- 为了确定新的治疗目标和有效的药物复发性WT.
主要方法:
- 从混合型WT细胞系产生部分重编程细胞 (WiT49-PRCs),通过引入多能性因子.
- 在体内研究,包括在小鼠体内植入囊,以评估瘤形成和转移潜力.
- 使用异原性WT和WiT49-PRC细胞系进行药物查,随后在患者衍生异种移植 (PDX) 中进行验证.
主要成果:
- 在小鼠中,WiT49-PRCs形成了脏瘤,肝脏和肺部转移,重复了布拉斯泰姆主导的WT.
- 药物查确定了对表皮或叶芽细胞占主导地位的WT敏感的特定药物.
- 基斯脱乙酶 (HDAC) 抑制剂在PDX中表现出与多克索鲁比辛相比具有普遍的有效性和优越的功效.
结论:
- WiT49-PRCs为研究和治疗高风险的转移性威尔姆斯瘤提供了有价值的模型.
- HDAC 抑制剂对于复发性或耐火性 WT 患者来说是一个有前途的治疗策略.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...